Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
ANTI-PD-1/CD47 BISPECIFIC ANTIBODY AND APPLICATION THEREOF
Document Type and Number:
WIPO Patent Application WO/2019/109357
Kind Code:
A1
Abstract:
The present invention provides a recombinant antibody. The recombinant antibody includes an anti-PD-1 antibody and human SIRPA extracellular domain. The N-terminus of the human SIRPA extracellular domain is linked to the C-terminus of the heavy chain of the anti-PD-1 antibody.

Inventors:
HUANG YING (CN)
ZHANG FAMING (CN)
XI GAN (CN)
Application Number:
PCT/CN2017/115323
Publication Date:
June 13, 2019
Filing Date:
December 08, 2017
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
HANX BIOPHARMACEUTICS INC (CN)
International Classes:
C07K16/28; A61K39/395; A61P35/00; C12N15/13; C12P21/08
Foreign References:
CN106456749A2017-02-22
CN107286242A2017-10-24
CN201610207741A2016-04-01
CN2016103814W2016-10-28
Other References:
TAO, HUA: "Targeting CD 47 Enhances the Efficacy of Anti-PD-1 and CTLA-4 in an Esophageal Squamous Cell Cancer Preclinical Model", ONCOLOGY RESEARCH FEATURING PRECLINICAL AND CLINICAL CANCER THERAPEUTICS, 2 November 2017 (2017-11-02), XP055540506, DOI: 10.3727/096504017X14900505020895
GUANG-TAO YU: "PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD 47/SIRPa axis in HPV negative head and neck squamous cell carcinoma", ONCOTARGET, vol. 6, no. 39, 7 November 2015 (2015-11-07), pages 42067 - 42080, XP055559721, DOI: 10.18632/oncotarget.5955
J. SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", SCIENCE PRESS
See also references of EP 3722312A4
Attorney, Agent or Firm:
TSINGYIHUA INTELLECTUAL PROPERTY LLC (CN)
Download PDF: